(+)-JQ1

Catalog No.S7110

(+)-JQ1 Chemical Structure

Molecular Weight(MW): 456.99

(+)-JQ1 is a BET bromodomain inhibitor, with IC50 of 77 nM/33 nM for BRD4(1/2) in cell-free assays, binding to all bromodomains of the BET family, but not to bromodomains outside the BET family.

Size Price Stock Quantity  
USD 270 In stock
USD 570 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

9 Customer Reviews

  • The BET protein inhibitor JQ1 reduces c-Myc expression and attenuates primary MCC cell proliferation. A, decreased c-Myc expression in MCC-3 and MCC-5 treated with JQ1 (800 nmol/L) for 72 hours by qRT-PCR and immunoblotting. The mRNA expression of target genes was normalized to that of MRPS2 and a value of 1.0 was assigned to the mRNA expression of target genes in the control group (means+SEM; **, P < 0.01 vs. control); b-actin was used as a loading control for immunoblotting.

    Cancer Res 2014 74(23), 7090-102. (+)-JQ1 purchased from Selleck.

    Immunohistochemical staining of xenograft tumor tissues. Immunohistochemical staining of xenograft tumor tissues with the indicated antibodies. p21-, p27-, p57-, and Ki67 positive cells (brown staining) were quantified at x400 magnification (meansSEM;**, P < 0.01;***, P < 0.001 vs. control); scale bars, 10 um.

    Cancer Res 2014 74(23), 7090-102. (+)-JQ1 purchased from Selleck.

  • (D) Effect of JQ1 on alterations of actin cytoskeleton in VEGF-induced HUVECs. The cells were pretreated with DMSO or JQ1 (100 nM) for 6 h, and stimulated with VEGF (10 ng/mL) for 12 h. F-actin (red) and nuclei (blue) were stained with phalloidin and DAPI, respectively. Representative images from 3 independent experiments.

    Sci Rep, 2016, 6:23770.. (+)-JQ1 purchased from Selleck.

    Sensitivity of BEZ235-resistant cells to JQ-1 using the MTT assay.

    Oncotarget, 2016, 6(7):5134-46.. (+)-JQ1 purchased from Selleck.

  • B. Repressed MCC-3 xenograft tumor growth upon combined treatment with MLN0128 and JQ1. Tumor bearing mice were treated with MLN0128 or vehicle at 1 mg/kg/day by oral gavage and JQ1 or vehicle at 50 mg/kg/day by i.p. injection for a period of 30 days. C. A more effective reduction of MCC-3 xenograft tumor growth in the group treated with combined therapy. Fold-reduction of tumor growth was calculated as average tumor growth of control group divided by average tumor growth of treatment group. Tumor growth was calculated as final average tumor volume minus initial average tumor volume in each group.

    Oncotarget, 2016, 7(6):6576-92.. (+)-JQ1 purchased from Selleck.

    Int J Stem Cells, 2018, 11(1):131-140. (+)-JQ1 purchased from Selleck.

  • JQ1 induces cell cycle arrest and apoptosis in Cal27 cells. (C) Cal27 cells were treated with JQ1 for 24 h and whole cell lysates were tested by western blot assays for the expression of cleaved-caspase-3. GAPDH was used as a loading control. (D) Apoptosis of Cal27 cells treated with JQ1 at 0 and 0.5 µM JQ1; *P<0.05 vs. control (the DMSO group)

    Oncol Rep, 2016, 36(4):1989-96.. (+)-JQ1 purchased from Selleck.

    immunofluorescence staining of BRD4 in ACC-LM and ACC-83 cells treated with JQ1 at the concentration of 1 µM for 24 h (×200).

    Biol Res, 2017, 50(1):19. (+)-JQ1 purchased from Selleck.

  • Effect of BET domain family inhibition on AMI damage in cardiomyocytes. (A) LDH and (B) CK-MB activity in the serum. #P<0.01 vs. sham group; @P<0.05 and &P<0.01 vs. AMI group. BET, bromodomain and extra-terminal; AMI, acute myocardial infarction; LDH, lactate dehydrogenase; CK-MB, creatine kinase MB isoenzyme.

    Exp Ther Med, 2015, 10(6):2319-2324.. (+)-JQ1 purchased from Selleck.

Purity & Quality Control

Choose Selective Epigenetic Reader Domain Inhibitors

Biological Activity

Description (+)-JQ1 is a BET bromodomain inhibitor, with IC50 of 77 nM/33 nM for BRD4(1/2) in cell-free assays, binding to all bromodomains of the BET family, but not to bromodomains outside the BET family.
Features (+)-JQ1 is more effective than (-)-JQ1.
Targets
BRD4 (2) [1]
(Cell-free assay)
BRD4 (1) [1]
(Cell-free assay)
33 nM 77 nM
In vitro

(+)-JQ1 enantiomer binds directly into the Kac binding site of BET bromodomains. (+)-JQ1 (500 nM) binds BRD4 competitively with chromatin resulting in differentiation and growth arrest of NMC cells. (+)-JQ1 (500 nM) attenuates rapid proliferation of NMC 797 and Per403 cell lines as demonstrated by reduced Ki67 staining. (+)-JQ1 (500 nM) potently decreases expression of both BRD4 target genes in NMC 797 cells. (+)-JQ1 inhibits cellular viability with IC50 of 4 nM in NMC 11060 cells. [1] (+)-JQ1 results in robust inhibition of MYC expression in MM cell lines. (+)-JQ1 inhibits proliferating of KMS-34 and LR5 with IC50 of 68 nM and 98 nM, respectively. (+)-JQ1 (500 nM)-treated MM.1S cells results in a pronounced decrease in the proportion of cells in S-phase, with a concomitant increase in cells arrested in G0/G1. (+)-JQ1 (500 nM) results in pronounced cellular senescence by beta-galactosidase staining. (+)-JQ1 (800 nM) exposure leads to a significant reduction in cell viability among the majority of CD138+ patient-derived MM samples tested. [2] (+)-JQ1 inhibits growth of LP-1 cells with GI50 of 98 nM. (+)-JQ1 (625 nM) results in an increase in the percentage of LP-1 cells in G0/G1. (+)-JQ1 (500 nM) suppresses the expression of MYC, BRD4 and CDK9 in LP-1 cells. [3] (+)-JQ1 (1 μM) activates HIV transcription in latently infected Jurkat T cells. (+)-JQ1 (50 μM) stimulates predominantly Tat-dependent HIV transcription in both Jurkat and HeLa cells. (+)-JQ1 (5 μM) induces Brd4 dissociation enables Tat to recruit SEC to HIV promoter and induce Pol II CTD phosphorylation and viral transcription in J-Lat A2 cells. JQ1 enables Tat to increase CDK9 T-loop phosphorylation and partially dissociates P-TEFb from 7SK snRNP in Jurkat T cells. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
K1  M4rwO2NmdGxiVnnhZoltcXS7IFHzd4F6 M2L0dlI2OC93MECvNVAxOCCwTR?= NHL4e2wzPC92OD:3NkBp NEfjcolFVVOR NF\p[ZJqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDpckBjd3SqIHTvd4UuKGGwZDD0bY1mNSCmZYDlcoRmdnRibXHucoVz NH\FXHozPjdyN{i4NS=>
BCPAP MlvVR4VtdCCYaXHibYxqfHliQYPzZZk> NVOzPWNLOjVyL{WwNE8yODByIH7N NHHySWEzPC92OD:3NkBp NHnEeohFVVOR MYHpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCrbjDic5RpKGSxc3WtJIFv\CC2aX3lMUBl\XCnbnTlcpQhdWGwbnXy MlvJNlY4ODd6OEG=
K1  NFi4OpFE\WyuIFP5Z4xmKEG|c3H5 M1;JR|I2OC93MECvNVAxOCCwTR?= NEfENIQ4OiCq NH;WbotFVVOR MlOzZZJz\XO2czDj[YxtKGO7Y3zlJIF1KEdyL1exJJBp[XOn Mk[xNlY4ODd6OEG=
BCPAP NYLXZVk6S2WubDDDfYNt\SCDc4PhfS=> MUCyOVAwPTByL{GwNFAhdk1? MWC3NkBp NYfZcGdGTE2VTx?= M4jMToFzemW|dIOgZ4VtdCCleXPs[UBifCCJMD;HNUBxcGG|ZR?= MXiyOlcxPzh6MR?=
Hep3B Mn7ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUmwMVExKM7:TR?= NFPBRWw2KGR? M{HXRmROW09? MmrMTWM2OD1yLkC4JO69VQ>? NE\Sb4YzPjV5NUG2Oy=>
HCCLM3 NFTLeGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4L0UFAuOTBizszN NU\HZ3NNPSCm NViyVWtJTE2VTx?= M2[5N2lEPTB;MD6xOEDPxE1? M{\WTVI3PTd3MU[3
HuH7 MkLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NILJWZMxNTFyIN88US=> NVKwb49iPSCm MWDEUXNQ M3H0PWlEPTB;MD6yNUDPxE1? NHWyTZQzPjV5NUG2Oy=>
HepG2 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYiwMVExKM7:TR?= NHLvd5o2KGR? NXq5U4JMTE2VTx?= NWS5SYNPUUN3ME2wMlM1KM7:TR?= NXfHfWM6OjZ3N{WxOlc>
SMMC7721 M1vr[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1zuVlAuOTBizszN MnLDOUBl MlizSG1UVw>? M2LsS2lEPTB;MD60NUDPxE1? M1;Te|I3PTd3MU[3
BEL7402 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVvvfnFYOC1zMDFOwG0> NYnMXpF{PSCm NHLDS21FVVOR MmPtTWM2OD1yLkS3JO69VQ>? NIizVHIzPjV5NUG2Oy=>
MHCC97H MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWTpPWQ{OC1zMDFOwG0> MkTLOUBl MnWwSG1UVw>? MXHJR|UxRTBwNEGg{txO M2PheVI3PTd3MU[3
Hep3B MlfDR4VtdCCFeXPs[UBCe3OjeR?= NUTWeGZHOC5zL{CuOU8zNjVizszN NXu1fYlbPDhiaB?= MV7EUXNQ MXvs[YFleyC2bzDhJJN2[nO2YX70bYFtKGGlY4XteYxifGmxbjDv[kBJS0NiY3XscJMhcW5ic4XiMWcyKHCqYYPlxsA> Mn\2NlY2PzVzNke=
HCCLM3 NUPldoVXS2WubDDDfYNt\SCDc4PhfS=> M1LEfFAvOS9yLkWvNk42KM7:TR?= NHvaR441QCCq MmXSSG1UVw>? MXfs[YFleyC2bzDhJJN2[nO2YX70bYFtKGGlY4XteYxifGmxbjDv[kBJS0NiY3XscJMhcW5ic4XiMWcyKHCqYYPlxsA> NGDHWG0zPjV5NUG2Oy=>
Hep3B MV\BdI9xfG:|aYOgRZN{[Xl? MYewMlEwOC53L{KuOUDPxE1? MnXFOFghcA>? MoH2SG1UVw>? MW\hZ5RqfmG2ZYOgZ4F{eGG|ZT2zJIFv\CClYYPwZZNmNTliZYjwdoV{e2mxbjDhcoQhcW6mdXPl[EBRSVKSIHPs[YF3[WenIHHzJJdmdGxiYYOgZ5l1d2Oqcn;t[UBkKHKnbHXhd4UhcW62bzD0bIUh[3m2b4DsZZNuKG[{b32gcYl1d2Oqb37kdoli NGjFPHEzPjV5NUG2Oy=>
HCCLM3 MXrBdI9xfG:|aYOgRZN{[Xl? NFu4eHcxNjFxMD61M|IvPSEQvF2= NUjJOHFMPDhiaB?= NET6Sm9FVVOR NIjCfZRi[3SrdnH0[ZMh[2G|cHHz[U0{KGGwZDDjZZNx[XOnLUmg[ZhxemW|c3nvckBidmRiaX7keYNm\CCSQWLQJINt\WG4YXflJIF{KHenbHygZZMh[3m2b3Podo9u\SClIILlcIVie2ViaX70c{B1cGViY4n0c5Bt[XOvIH\yc40hdWm2b3Poc45lemmj M1HJZ|I3PTd3MU[3
A549 NX3k[JBNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFryW4oxNjFvMUCg{txO MonQO|IhcA>? NVzac2lCcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M{XsSlI3PDF3MkK1
H157 M2HzUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1z3[FAvOS1zMDFOwG0> NULtcndTPzJiaB?= NGG0NWNqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NXHkXYhiOjZ2MUWyNlU>
H1299 NIXW[lZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYqwMlEuOTBizszN MnvFO|IhcA>? MUDpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NHzXTHUzPjRzNUKyOS=>
A549 NWj6enliTnWwY4Tpc44hSXO|YYm= MV2xM|IvPS93IN88US=> NWP2cJozOTJiaB?= M2mx[OKhf2Wja3z5JIRm[3KnYYPl[EBD[2xvMjDs[ZZmdHN? NGLyRnUzPjRzNUKyOS=>
H1299 MnTDSpVv[3Srb36gRZN{[Xl? MVyxM|IvPS93IN88US=> MVuxNkBp NH62[ojDqHenYXvsfUBl\WO{ZXHz[YQhSmOuLUKgcIV3\Wy| MoLDNlY1OTV{MkW=
H157 M3nLV2Z2dmO2aX;uJGF{e2G7 MmnzNU8zNjVxNTFOwG0> NF35Z3gyOiCq NIfpd2Rl\WO{ZXHz[YQhTFJ2IHX4dJJme3Orb36= NYCwPXA4OjZ2MUWyNlU>
H1299 MlK0SpVv[3Srb36gRZN{[Xl? MUKxM|IvPS93IN88US=> MUOxNkBp NUnZW3Fz\GWlcnXhd4VlKESUNDDlfJBz\XO|aX;u MkjxNlY1OTV{MkW=
C8161 MUfD[YxtKF[rYXLpcIl1gSCDc4PhfS=> Ml3xNE0zKM7:TR?= NVrFfnhIPCCm MX;EUXNQ MUjk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MXqyOlM6PzJ{Mx?=
Mel285 NEPx[pRE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NGjxb4MxNTJizszN M{jU[FQh\A>? NGfaOW5FVVOR NYHaPWh{\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MYmyOlM6PzJ{Mx?=
Mel290 M{HHWWNmdGxiVnnhZoltcXS7IFHzd4F6 MoD4NE0zKM7:TR?= M{njWlQh\A>? MVPEUXNQ NXrWXJZy\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NWHSSIx6OjZ|OUeyNlM>
92.1 MYTD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MX6wMVIh|ryP M2nlT|Qh\A>? NXjqdJVRTE2VTx?= MkPn[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NILIWFIzPjN7N{KyNy=>
Omm1.3 MknTR4VtdCCYaXHibYxqfHliQYPzZZk> NXX5NlFtOC1{IN88US=> MXS0JIQ> MXzEUXNQ MXzk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MWSyOlM6PzJ{Mx?=
Mel202 MkSxR4VtdCCYaXHibYxqfHliQYPzZZk> MWOwMVIh|ryP NEPTcFQ1KGR? MlLuSG1UVw>? NXnWXllu\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy Mn2xNlY{QTd{MkO=
Mel270 M{[wUGNmdGxiVnnhZoltcXS7IFHzd4F6 MUWwMVIh|ryP MXe0JIQ> M2DTN2ROW09? NVixWJJX\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MkLaNlY{QTd{MkO=
Omm1 NIrYRWhE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M2jYWlAuOiEQvF2= M1LwXFQh\A>? M2TwPGROW09? NWThUWVj\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NUjxWFVlOjZ|OUeyNlM>
92.1 NXLBR|Q{SXCxcITvd4l{KEG|c3H5 M2HDdlUxOCCwTR?= MWG0PEBp NX\kfXVETE2VTx?= MXTpcoR2[2W|IHHwc5B1d3Orcx?= NHnZcJIzPjN7N{KyNy=>
Omm1.3 MoqzRZBweHSxc3nzJGF{e2G7 MkPVOVAxKG6P MVW0PEBp M1XLcGROW09? NEHRd|BqdmS3Y3XzJIFxd3C2b4Ppdy=> M3;ne|I3Ozl5MkKz
92.1 MUTD[YxtKEO7Y3zlJGF{e2G7 MVK1NFAhdk1? M{KyOlI1NzR6L{eyJIg> NGjtSHdFVVOR NIDOUZZqdmS3Y3XzJJRp\SClZXzsJIFk[3WvdXzheIlwdiCjdDDzeYIuTzIEoB?= MlXxNlY{QTd{MkO=
Omm1.3 MUnD[YxtKEO7Y3zlJGF{e2G7 MYi1NFAhdk1? NETaeJIzPC92OD:3NkBp NEC1eoZFVVOR NIP0SnNqdmS3Y3XzJJRp\SClZXzsJIFk[3WvdXzheIlwdiCjdDDzeYIuTzIEoB?= NYe5bHU2OjZ|OUeyNlM>
A549 NVOzSFMxTnWwY4Tpc44hSXO|YYm= MonwNVAxNzRyMD:xNFAxKG6P Mn\PNlQhcA>? M1r6TpVxemWpdXzheIV{KGGwZDDhZ5RqfmG2ZYOgV2lTXDF? NUHvd5pvOjZ{MUKxPVk>
MCF-7 Mn3ySpVv[3Srb36gRZN{[Xl? MUixNFAwPDByL{GwNFAhdk1? M{DUXlI1KGh? NUTOe4h2fXC{ZXf1cIF1\XNiYX7kJIFkfGm4YYTld{BUUVKWMR?= MWeyOlIyOjF7OR?=
HEK293 NVPzZ3BrTnWwY4Tpc44hSXO|YYm= Ml7xNVAxNzRyMD:xNFAxKG6P MVeyOEBp NYPzemNbfXC{ZXf1cIF1\XNiYX7kJIFkfGm4YYTld{BUUVKWMR?= NW\3fox5OjZ{MUKxPVk>
858 NUXuRndIS2WubDDWbYFjcWyrdImgRZN{[Xl? MlvKNE0yKM7:TR?= M3fR[lUh\A>? NUDUZmptTE2VTx?= MkHh[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NEj3T3YzPjJyNkOzNy=>
DDR2L63V MYPD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MWiwMVEh|ryP NXG4R4htPSCm NXLXdmN[TE2VTx?= NFXQd3Vl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= M{LoflI3OjB4M{Oz
BE(2)-C MYDD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MmjkNUDPxE1? MY[xMVQh\A>? NGDJTXhl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgd4lodmmoaXPhcpRtgQ>? Mn3VNlYxPjd2NkS=
IMR-32 M3LldGNmdGxiVnnhZoltcXS7IFHzd4F6 MWqxJO69VQ>? M1PDT|EuPCCm Mnjz[IVkemWjc3XzJINmdGxidnnhZoltcXS7IIPp[45q\mmlYX70cJk> MmW2NlYxPjd2NkS=
JF Mn3OR4VtdCCYaXHibYxqfHliQYPzZZk> MljUNUDPxE1? MXSxMVQh\A>? Mk\t[IVkemWjc3XzJINmdGxidnnhZoltcXS7IIPp[45q\mmlYX70cJk> NWC4T254OjZyNke0OlQ>
BE(2)-M17 NYHPUG5DS2WubDDWbYFjcWyrdImgRZN{[Xl? NUDJTYZ[OSEQvF2= NYS2eHdNOS12IHS= M4jZWIRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDzbYdvcW[rY3HueIx6 MUeyOlA3PzR4NB?=
SK-N-SH NGTKO2ZE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MUSxJO69VQ>? MXexMVQh\A>? M4HjVYRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDzbYdvcW[rY3HueIx6 NIHmN5UzPjB4N{S2OC=>
SK-N-DZ  MkTHR4VtdCCYaXHibYxqfHliQYPzZZk> M{XKWlEh|ryP NHfFU44yNTRiZB?= MYPk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHlic3nncolncWOjboTsfS=> M3LpS|I3ODZ5NE[0
HMC-1.1  NYrTXHpKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;NfFUuPTByMDDuUS=> MmfWOFghcA>? NX;GOmZHTE2VTx?= NX\vNJhJcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NE\Bb|YzPjB3NUOwNy=>
HMC-1.2 NFm0RmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYT0TmkzPS13MECwJI5O NFHxWYo1QCCq MkW0SG1UVw>? MWjpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NIfkW2kzPjB3NUOwNy=>
ROSA KIT WT  Ml\jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HrWlUuPTByMDDuUS=> NFr5WG41QCCq MVjEUXNQ NH\ld3hqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? Mn3SNlYxPTV|MEO=
ROSA KIT D816V MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUC5PXBpPS13MECwJI5O MV:0PEBp MmeySG1UVw>? M{DEdolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz Mke3NlYxPTV|MEO=
HMC-1.1  NIToV5lCeG:ydH;zbZMhSXO|YYm= MXuyNFAuPTByMDDuUS=> MVu0PEBp NELmXWxFVVOR M3XPPIlv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M4q0WVI3ODV3M{Cz
HMC-1.2 MV3BdI9xfG:|aYOgRZN{[Xl? MWiyNFAuPTByMDDuUS=> MYi0PEBp MW\EUXNQ Ml65bY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MoLCNlYxPTV|MEO=
ROSA KIT WT  M3TTcGFxd3C2b4Ppd{BCe3OjeR?= MVqyNFAuPTByMDDuUS=> MkjZOFghcA>? MmXpSG1UVw>? NY\OZVBpcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NETXTZUzPjB3NUOwNy=>
ROSA KIT D816V NHXSZZlCeG:ydH;zbZMhSXO|YYm= NUT2RZh5OjByLUWwNFAhdk1? MnW0OFghcA>? MVfEUXNQ NFvsOoNqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MkDnNlYxPTV|MEO=
494H MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmDPO|IhcA>? MULEUXNQ M4q5R2lEPTB;MD6xNlLDuTBwMEC0JO69VQ>? M2jtZ|I2QTR2NU[2
493H NHTkVmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnm0O|IhcA>? M1rxSmROW09? NVn6S|ZHUUN3ME2wMlA1P8LzMD6wNFkh|ryP MlHnNlU6PDR3Nk[=
716H MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVm3NkBp MlLJSG1UVw>? MWDJR|UxRTBwMkGyxtExNjB|NDFOwG0> NWHrO2RVOjV7NES1OlY>
148I NXK3S4JRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2i0fVczKGh? M3PXNGROW09? NYXZcZR2UUN3ME2wMlI5PMLzMD6wN|Uh|ryP MUWyOVk1PDV4Nh?=
98Sc MkTWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlnLO|IhcA>? NGPTV3VFVVOR M{HrU2lEPTB;MD6xNVXDuTBwMEC0JO69VQ>? MlvWNlU6PDR3Nk[=
89R MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3HHRlczKGh? M1zkdGROW09? MV;JR|UxRTBwMUK2xtExNjByMzFOwG0> NFzmUlIzPTl2NEW2Oi=>
494L NUPRcJJTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmTkO|IhcA>? MmHrSG1UVw>? NF3xc|hKSzVyPUCuN|E4yrFyLkCxNkDPxE1? Mne2NlU6PDR3Nk[=
493L M3nCdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\iOIE4OiCq NW\jbWk1TE2VTx?= NGGwOIZKSzVyPUCuNFUxyrFyLkCxNUDPxE1? MmjGNlU6PDR3Nk[=
148L MljNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LTNVczKGh? MWHEUXNQ NUjMd3pUUUN3ME2wMlE1PsLzMD6wNVch|ryP MVyyOVk1PDV4Nh?=
98L MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXS3NIh{PzJiaB?= M4TNbWROW09? NFW4WlZKSzVyPUCuN|A6yrFyLkCyPUDPxE1? NHnHb20zPTl2NEW2Oi=>
OS17 NEX4d2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVS3NkBp NEDHd3FFVVOR NGLNS5RKSzVyPUCuNFc6yrFyLkCwN{DPxE1? NXGwUJJEOjV7NES1OlY>
OS9 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGH5eoI4OiCq NIfYVYVFVVOR Ml;KTWM2OD1yLkSwOuKyOC5yMkig{txO NXTNeGI6OjV7NES1OlY>
MG63 NIW1dIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2rkTFczKGh? M{LvPGROW09? NWGzfG9yUUN3ME2wMlEyPMLzMD6wNlUh|ryP NYj4UpMzOjV7NES1OlY>
SAOS2 NWLYW2dpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUOy[VRrPzJiaB?= NFjI[WlFVVOR M{DDWWlEPTB;MD6yNVfDuTBwMECzJO69VQ>? MV6yOVk1PDV4Nh?=
U2OS NUDWWW5uT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlPKO|IhcA>? NX7oZo9VTE2VTx?= MV\JR|UxRTBwMUm4xtExNjByODFOwG0> MUWyOVk1PDV4Nh?=
SJSA-1 M{jlTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fp[VczKGh? M{D2NmROW09? M2LtZWlEPTB;MD6xNFDDuTBwMEGwJO69VQ>? NYXpbnJ3OjV7NES1OlY>
494H MlTDRZBweHSxc3nzJGF{e2G7 NHPmbGsxNjJ3L{CuOU8yNjBizszN MlOwNlQhcA>? NYPUV|VpTE2VTx?= MXLpcoNz\WG|ZYOgcIV3\Wy|IH;mJINt\WG4ZXSgZ4F{eGG|ZT2zxsA> NXT4RpBmOjV7NES1OlY>
148I Moe1RZBweHSxc3nzJGF{e2G7 MkfnNE4zPS9yLkWvNU4xKM7:TR?= NWPxfI0yOjRiaB?= M1vT[WROW09? NUfac3oycW6lcnXhd4V{KGyndnXsd{Bw\iClbHXheoVlKGOjc4Dhd4UuO8Li MUeyOVk1PDV4Nh?=
OS17 NFP6fodCeG:ydH;zbZMhSXO|YYm= M2DielAvOjVxMD61M|EvOCEQvF2= M4ntUFI1KGh? MmPXSG1UVw>? MWjpcoNz\WG|ZYOgcIV3\Wy|IH;mJINt\WG4ZXSgZ4F{eGG|ZT2zxsA> NHHLS3UzPTl2NEW2Oi=>
494H NEe0eGlCeG:ydH;zbZMhSXO|YYm= MonGNgKBkc7:TR?= MWG0PEBp M{\XVmROW09? M2Oz[olv\HWlZYOgZ4VtdCCjcH;weI9{cXNic3nncolncWOjboTsfS=> M4jPc|I2QTR2NU[2
148I MkXvRZBweHSxc3nzJGF{e2G7 MYSx5qCK|ryP M13JS|Q5KGh? NIX4cpNFVVOR MmjYbY5lfWOnczDj[YxtKGGyb4D0c5NqeyC|aXfubYZq[2GwdHz5 M1XTRlI2QTR2NU[2
OS17 MUHBdI9xfG:|aYOgRZN{[Xl? M3LNTlHjiIoQvF2= MXG0PEBp NVWwRmV5TE2VTx?= MlL6bY5lfWOnczDj[YxtKGGyb4D0c5NqeyC|aXfubYZq[2GwdHz5 NILrWYgzPTl2NEW2Oi=>
MOLM13 NHHzbJZCeG:ydH;zbZMhSXO|YYm= MoLhNlUxKG6P M{DBWFQ5KGh? NWLmNXhRTE2VTx?= MnHSbY5lfWOnczDzbYdvcW[rY3HueIx6KGGyb4D0c5NqeyClb4Ty[YF1dWWwdDD3bZRpKHG3aYrhdpRqdmmk NX\NNpFGOjVyNUO4NlU>
MV4-11  NIjvSWhCeG:ydH;zbZMhSXO|YYm= M4CxcFI2OCCwTR?= M3TJVVQ5KGh? NIm3fXVFVVOR NG\Ge49qdmS3Y3XzJJNq\26rZnnjZY51dHliYYDvdJRwe2m|IHPveJJm[XSvZX70JJdqfGhicYXpfoFzfGmwaXK= Mke1NlUxPTN6MkW=
MOLM13 NIrJdHdHfW6ldHnvckBCe3OjeR?= M{jLOFI2OCCwTR?= M2fP[FI1KGh? NHHDWlhFVVOR MVTlcohidmOnczDxeYl7[XK2aX7pZk1qdmS3Y3XkJI1wemVicEKxMEBDUU1uIHHu[EBkdGWjdnXkJHBCWlB? MVSyOVA2Ozh{NR?=
MV4-11  MoXSSpVv[3Srb36gRZN{[Xl? M1r5elI2OCCwTR?= NHvNd3gzPCCq M3PETWROW09? Mny1[Y5p[W6lZYOgdZVqgmG{dHnubYIucW6mdXPl[EBud3KnIICyNUwhSkmPLDDhcoQh[2ynYY\l[EBRSVKS NIPBNZgzPTB3M{iyOS=>
MOLM13 NWS3XnRwSXCxcITvd4l{KEG|c3H5 NVv5[VlFOjVyIH7N NETneVE1QCCq MX;EUXNQ NHHEN5pqdmS3Y3XzJJNq\26rZnnjZY51dHliYYDvdJRwe2m|IHPveJJm[XSvZX70JJdqfGhicH;uZZRqdmmk MXKyOVA2Ozh{NR?=
MV4-11  NUTZVpRySXCxcITvd4l{KEG|c3H5 MXuyOVAhdk1? MmD6OFghcA>? MlXlSG1UVw>? MonobY5lfWOnczDzbYdvcW[rY3HueIx6KGGyb4D0c5NqeyClb4Ty[YF1dWWwdDD3bZRpKHCxbnH0bY5q[g>? MkntNlUxPTN6MkW=
Hela M{fJTGNmdGxiVnnhZoltcXS7IFHzd4F6 Mn7oNE02ODBibl2= NEPYeHE4OiCq NYrL[4pOTE2VTx?= M1TibYRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= M2fHTFI2ODB7Mkm1
HBL-1 MmDJR4VtdCCYaXHibYxqfHliQYPzZZk> MlSwNE02ODBibl2= Mk\2O|IhcA>? NInTS2JFVVOR NIPLUZRl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NFH2VGszPTByOUK5OS=>
HLY-1 NHvTbJlE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NEjLXJAxNTVyMDDuUS=> MUS3NkBp M3[xRWROW09? Mkiz[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MXiyOVAxQTJ7NR?=
OCI-Ly3 MV;D[YxtKF[rYXLpcIl1gSCDc4PhfS=> MlPvNE02ODBibl2= NV;zfmdPPzJiaB?= MlHHSG1UVw>? MYTk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M1:0SFI2ODB7Mkm1
OCI-Ly10 M4TubmNmdGxiVnnhZoltcXS7IFHzd4F6 NVG4WItqOC13MECgcm0> MnPyO|IhcA>? MWjEUXNQ M3m3SYRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MXKyOVAxQTJ7NR?=
SU-DHL-4 NF7OeHJE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MmLjNE02ODBibl2= MX:3NkBp M4exVmROW09? NX7IVZps\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NGLtTWYzPTByOUK5OS=>
SU-DHL-5 NIfyWYdE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MXWwMVUxOCCwTR?= NV\ydXh3PzJiaB?= NVfQNWU2TE2VTx?= MVTk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NE[ybVgzPTByOUK5OS=>
SU-DHL-6 MWTD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MkP3NE02ODBibl2= NHzVV4c4OiCq MWLEUXNQ M3zMdoRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NWnmOJNzOjVyMEmyPVU>
SU-DHL-10 NV\DNm8{S2WubDDWbYFjcWyrdImgRZN{[Xl? NYnOfYw1OC13MECgcm0> MljtO|IhcA>? NGjmcWRFVVOR NV\2VZhr\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NYi4cWZlOjVyMEmyPVU>
RC-K8 NHyyVlJE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NWTXSYdtOC13MECgcm0> NGLqeo84OiCq MnvKSG1UVw>? MV7k[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MWCyOVAxQTJ7NR?=
OCI-Ly8 MX\D[YxtKF[rYXLpcIl1gSCDc4PhfS=> NUnPZVZ6OC13MECgcm0> NYjvSJUyPzJiaB?= MmHISG1UVw>? M{nhSIRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= M{nCPFI2ODB7Mkm1
OCL-Ly18 MYPD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NX;VW|JNOC13MECgcm0> MmO2O|IhcA>? MmfGSG1UVw>? M1ThRYRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= M4izXlI2ODB7Mkm1
OCI-Ly3 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7KNVczNzJ3MD:1NFAhdk1? MlyyNk84KGR? M13DcGROW09? Moe3bY5lfWOnczDj[YxtNWO7Y3zlJIFzemW|dDDheEB{fWJvR{Gge4l1cCCvaX7pcYFtKGOnbHyg[IVifGkEoB?= MYmyOVAxQTJ7NR?=
OCI-Ly8 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2LFUVE4Oi9{NUCvOVAxKG6P NXnsSHdPOi95IHS= MX;EUXNQ MUnpcoR2[2W|IHPlcIwu[3mlbHWgZZJz\XO2IHH0JJN2[i2JMTD3bZRpKG2rbnntZYwh[2WubDDk[YF1cMLi Mo\NNlUxODl{OUW=
SU-DHL-4 NUjB[G5yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX7OUZdVOTd{L{K1NE82ODBibl2= MVOyM|ch\A>? Mnr0SG1UVw>? NHP3OJVqdmS3Y3XzJINmdGxvY4njcIUh[XK{ZYP0JIF1KHO3Yj3HNUB4cXSqIH3pcolu[WxiY3XscEBl\WG2aNMg MXuyOVAxQTJ7NR?=
SU-DHL-10 Ml;US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVixO|IwOjVyL{WwNEBvVQ>? MXSyM|ch\A>? NH\hdFFFVVOR NFf0b2NqdmS3Y3XzJINmdGxvY4njcIUh[XK{ZYP0JIF1KHO3Yj3HNUB4cXSqIH3pcolu[WxiY3XscEBl\WG2aNMg M{K0Z|I2ODB7Mkm1
OCI-Ly3 NWDOUndISXCxcITvd4l{KEG|c3H5 NY\ISZYyOTd{L{K1NEBvVQ>? M1jINVdl M{PHbGROW09? M2HiWYlv[3KnYYPld{Bk[XOyYYPlMVMwPyCjY4Tpeol1gcLic3nncolncWOjboTsfS=> MmT6NlUxODl{OUW=
OCI-Ly8 MojRRZBweHSxc3nzJGF{e2G7 NW[1VJdPOTd{L{K1NEBvVQ>? MlSwO4Q> NWeyO2FuTE2VTx?= MoG1bY5kemWjc3XzJINie3Cjc3WtN{84KGGldHn2bZR6yqC|aXfubYZq[2GwdHz5 NH7pfo0zPTByOUK5OS=>
SU-DHL-4 NYrmWGZVSXCxcITvd4l{KEG|c3H5 MVOxO|IwOjVyIH7N M13lZldl M1;jUWROW09? M2LrPIlv[3KnYYPld{Bk[XOyYYPlMVMwPyCjY4Tpeol1gcLic3nncolncWOjboTsfS=> MmCxNlUxODl{OUW=
SU-DHL-10 NES2R4NCeG:ydH;zbZMhSXO|YYm= M2Hj[VE4Oi9{NUCgcm0> NHPscWI4\A>? NHm0W4FFVVOR MmHobY5kemWjc3XzJINie3Cjc3WtN{84KGGldHn2bZR6yqC|aXfubYZq[2GwdHz5 NXXDNJd{OjVyMEmyPVU>

... Click to View More Cell Line Experimental Data

In vivo (+)-JQ1 (50 mg/kg) inhibits tumors growth in mice with NMC 797 xenografts. (+)-JQ1 (50 mg/kg) results in effacement of NUT nuclear speckles in mice with NMC 797 xenografts, consistent with competitive binding to nuclear chromatin. (+)-JQ1 (50 mg/kg) induces strong (grade 31) keratin expression in NMC 797 xenografts. (+)-JQ1 (50 mg/kg) promotes differentiation, tumor regression and prolonged survival in mice models of NMC xenografts. [1] (+)-JQ1 (50 mg/kg) results in a significant prolongation in overall survival of SCID-beige mice orthotopically xenografted after intravenous injection with MM.1S-luc+ cells compared to vehicle-treated animals. [2] (+)-JQ1 (50 mg/kg i.p.) leads to a highly significant increase in survival of mice bearing Raji xenografts. [3]

Protocol

Cell Research:

[1]

+ Expand
  • Cell lines: MC 11060 cells
  • Concentrations: ~500 nM
  • Incubation Time: 48 hours
  • Method:

    Cells are seeded into white, 384-well microtiter plates at 500 cells per well in a total volume of 50 μL media. The 797, TT and TE10 cells are grown in DMEM containing 1% penicillin/streptomycin and 10% FBS. The Per403 cells are grown in DMEM containing 1 % penicillin/streptomycin and 20% FBS. Patient-derived NMC 11060 cells are grown in RPMI with 10% FBS and 1% penicillin/streptomycin. (+)-JQ1 is delivered to microtiter assay plates by robotic pin transfer. Following a 48 hours incubation at 37℃, cells are lysed and wells are assessed for total ATP content using a commercial proliferation assay. Replicate measurements are analyzed with respect to dose and estimates of IC50 are calculated by logistic regression (GraphPad Prism).


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: Mice bearing NMC 797 xenografts
  • Formulation: 5% DMSO in 5% dextrose
  • Dosages: 50 mg/kg
  • Administration: intraperitoneal injection
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 91 mg/mL warmed (199.12 mM)
Ethanol 91 mg/mL (199.12 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 456.99
Formula

C23H25ClN4O2S

CAS No. 1268524-70-4
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    How can I reconstitute the compound for in vivo injection?

  • Answer:

    JQ1 does not dissolve in water/PBS. The vehicle we recommend is 2% DMSO+30% PEG 300+5% Tween 80+ddH2O. The compound can be dissolved in the vehicle at 5mg/ml and you can use it for IV injection.

Epigenetic Reader Domain Signaling Pathway Map

Epigenetic Reader Domain Inhibitors with Unique Features

Tags: buy (+)-JQ1 | (+)-JQ1 supplier | purchase (+)-JQ1 | (+)-JQ1 cost | (+)-JQ1 manufacturer | order (+)-JQ1 | (+)-JQ1 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID